Argininosuccinate lyase is a potential therapeutic target in breast cancer

Huang,Hau-Lun; Chen,Wei-Ching; Hsu,Hui-Ping; Cho,Chien-Yu; Hung,Yu‑Hsuan; Wang,Chih-Yang; Lai,Ming-Derg

doi:10.3892/or.2015.4280

Argininosuccinate lyase is a potential therapeutic target in breast cancer

Authors:
- Hau-Lun Huang
- Wei-Ching Chen
- Hui-Ping Hsu
- Chien-Yu Cho
- Yu‑Hsuan Hung
- Chih-Yang Wang
- Ming-Derg Lai
View Affiliations

Affiliations: Institute of Basic Medical Sciences, College of Medicine, National Cheng Kung University, Tainan City 701, Taiwan, R.O.C., Department of Surgery, College of Medicine, National Cheng Kung University, Tainan City 701, Taiwan, R.O.C.
Published online on: September 16, 2015 https://doi.org/10.3892/or.2015.4280
Pages: 3131-3139

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Arginine is a non-essential amino acid that modulates nitric oxide production and cancer homeostasis. In our previous study, we observed that blocking argininosuccinate lyase (ASL) attenuates tumor progression in liver cancer. However, the role of ASL in human breast cancer has been studied to a lesser degree. In the present study, we investigated the effect of targeting ASL in breast cancer. We found that ASL was induced by ER stress and was significantly upregulated in breast cancer tissues compared to that in the corresponding normal tissues. Downregulation of ASL inhibited the growth of breast cancer in vitro and in vivo. The level of cell cycle-related gene, cyclin A2, was reduced and was accompanied by a delay in G2/M transition. ASL shRNA-induced cell inhibition was rescued by exogenous cyclin A2. Furthermore, autophagy was observed in the cells expressing ASL shRNA, and inhibition of autophagy reduced cell growth, indicating that autophagy played a cell survival role in the ASL knockdown cells. Moreover, inhibition of ASL reduced NO content. Introduction of the NO donor partially restored the growth inhibition by ASL shRNA. Thus, the mechanism induced by ASL shRNA which occurred in human breast cancer may be attributed to a decrease in cyclin A2 and NO.

View Figures

View References

1	McDonnell DP, Park S, Goulet MT, Jasper J, Wardell SE, Chang CY, Norris JD, Guyton JR and Nelson ER: Obesity, cholesterol metabolism, and breast cancer pathogenesis. Cancer Res. 74:4976–4982. 2014. View Article : Google Scholar : PubMed/NCBI
2	Stebbing J, Sharma A, North B, Athersuch TJ, Zebrowski A, Pchejetski D, Coombes RC, Nicholson JK and Keun HC: A metabolic phenotyping approach to understanding relationships between metabolic syndrome and breast tumour responses to chemotherapy. Ann Oncol. 23:860–866. 2012. View Article : Google Scholar
3	Hirayama A, Kami K, Sugimoto M, Sugawara M, Toki N, Onozuka H, Kinoshita T, Saito N, Ochiai A, Tomita M, et al: Quantitative metabolome profiling of colon and stomach cancer microenvironment by capillary electrophoresis time-of-flight mass spectrometry. Cancer Res. 69:4918–4925. 2009. View Article : Google Scholar : PubMed/NCBI
4	Qiu F, Chen YR, Liu X, Chu CY, Shen LJ, Xu J, Gaur S, Forman HJ, Zhang H, Zheng S, et al: Arginine starvation impairs mitochondrial respiratory function in ASS1-deficient breast cancer cells. Sci Signal. 7:ra312014. View Article : Google Scholar : PubMed/NCBI
5	Possemato R, Marks KM, Shaul YD, Pacold ME, Kim D, Birsoy K, Sethumadhavan S, Woo HK, Jang HG, Jha AK, et al: Functional genomics reveal that the serine synthesis pathway is essential in breast cancer. Nature. 476:346–350. 2011. View Article : Google Scholar : PubMed/NCBI
6	Amelio I, Cutruzzolá F, Antonov A, Agostini M and Melino G: Serine and glycine metabolism in cancer. Trends Biochem Sci. 39:191–198. 2014. View Article : Google Scholar : PubMed/NCBI
7	Wu G and Morris SM Jr: Arginine metabolism: Nitric oxide and beyond. Biochem J. 336:1–17. 1998. View Article : Google Scholar : PubMed/NCBI
8	Vissers YL, Dejong CH, Luiking YC, Fearon KC, von Meyenfeldt MF and Deutz NE: Plasma arginine concentrations are reduced in cancer patients: Evidence for arginine deficiency? Am J Clin Nutr. 81:1142–1146. 2005.PubMed/NCBI
9	Daly JM, Reynolds J, Thom A, Kinsley L, Dietrick-Gallagher M, Shou J and Ruggieri B: Immune and metabolic effects of arginine in the surgical patient. Ann Surg. 208:512–523. 1988. View Article : Google Scholar : PubMed/NCBI
10	Talamonti MS, Kim SP, Yao KA, Wayne JD, Feinglass J, Bennett CL and Rao S: Surgical outcomes of patients with gastric carcinoma: The importance of primary tumor location and microvessel invasion. Surgery. 134:720–729. 2003. View Article : Google Scholar : PubMed/NCBI
11	Yerushalmi HF, Besselsen DG, Ignatenko NA, Blohm-Mangone KA, Padilla-Torres JL, Stringer DE, Guillen JM, Holubec H, Payne CM and Gerner EW: Role of polyamines in arginine-dependent colon carcinogenesis in Apc^Min^/+ mice. Mol Carcinog. 45:764–773. 2006. View Article : Google Scholar : PubMed/NCBI
12	Park KG, Heys SD, Blessing K, Kelly P, McNurlan MA, Eremin O and Garlick PJ: Stimulation of human breast cancers by dietary L-arginine. Clin Sci. 82:413–417. 1992. View Article : Google Scholar : PubMed/NCBI
13	Yeatman TJ, Risley GL and Brunson ME: Depletion of dietary arginine inhibits growth of metastatic tumor. Arch Surg. 126:1376–1382. 1991. View Article : Google Scholar : PubMed/NCBI
14	Ma Q, Wang Y, Gao X, Ma Z and Song Z: L-arginine reduces cell proliferation and ornithine decarboxylase activity in patients with colorectal adenoma and adenocarcinoma. Clin Cancer Res. 13:7407–7412. 2007. View Article : Google Scholar : PubMed/NCBI
15	Feun L, You M, Wu CJ, Kuo MT, Wangpaichitr M, Spector S and Savaraj N: Arginine deprivation as a targeted therapy for cancer. Curr Pharm Des. 14:1049–1057. 2008. View Article : Google Scholar : PubMed/NCBI
16	Phillips MM, Sheaff MT and Szlosarek PW: Targeting arginine-dependent cancers with arginine-degrading enzymes: Opportunities and challenges. Cancer Res Treat. 45:251–262. 2013. View Article : Google Scholar
17	Delage B, Fennell DA, Nicholson L, McNeish I, Lemoine NR, Crook T and Szlosarek PW: Arginine deprivation and arginino-succinate synthetase expression in the treatment of cancer. Int J Cancer. 126:2762–2772. 2010.PubMed/NCBI
18	Shen LJ and Shen WC: Drug evaluation: ADI-PEG-20 - a PEGylated arginine deiminase for arginine-auxotrophic cancers. Curr Opin Mol Ther. 8:240–248. 2006.PubMed/NCBI
19	Shen LJ, Beloussow K and Shen WC: Modulation of arginine metabolic pathways as the potential anti-tumor mechanism of recombinant arginine deiminase. Cancer Lett. 231:30–35. 2006. View Article : Google Scholar
20	Dillon BJ, Prieto VG, Curley SA, Ensor CM, Holtsberg FW, Bomalaski JS and Clark MA: Incidence and distribution of argininosuccinate synthetase deficiency in human cancers: A method for identifying cancers sensitive to arginine deprivation. Cancer. 100:826–833. 2004. View Article : Google Scholar : PubMed/NCBI
21	Ensor CM, Holtsberg FW, Bomalaski JS and Clark MA: Pegylated arginine deiminase (ADI-SS PEG_20,000 mw) inhibits human melanomas and hepatocellular carcinomas in vitro and in vivo. Cancer Res. 62:5443–5450. 2002.PubMed/NCBI
22	Bowles TL, Kim R, Galante J, Parsons CM, Virudachalam S, Kung HJ and Bold RJ: Pancreatic cancer cell lines deficient in argininosuccinate synthetase are sensitive to arginine deprivation by arginine deiminase. Int J Cancer. 123:1950–1955. 2008. View Article : Google Scholar : PubMed/NCBI
23	Yoon CY, Shim YJ, Kim EH, Lee JH, Won NH, Kim JH, Park IS, Yoon DK and Min BH: Renal cell carcinoma does not express argininosuccinate synthetase and is highly sensitive to arginine deprivation via arginine deiminase. Int J Cancer. 120:897–905. 2007. View Article : Google Scholar
24	Feun LG, Marini A, Walker G, Elgart G, Moffat F, Rodgers SE, Wu CJ, You M, Wangpaichitr M, Kuo MT, et al: Negative argininosuccinate synthetase expression in melanoma tumours may predict clinical benefit from arginine-depleting therapy with pegylated arginine deiminase. Br J Cancer. 106:1481–1485. 2012. View Article : Google Scholar : PubMed/NCBI
25	Erez A, Nagamani SC, Shchelochkov OA, Premkumar MH, Campeau PM, Chen Y, Garg HK, Li L, Mian A, Bertin TK, et al: Requirement of argininosuccinate lyase for systemic nitric oxide production. Nat Med. 17:1619–1626. 2011. View Article : Google Scholar : PubMed/NCBI
26	Turner MA, Simpson A, McInnes RR and Howell PL: Human argininosuccinate lyase: A structural basis for intragenic complementation. Proc Natl Acad Sci USA. 94:9063–9068. 1997. View Article : Google Scholar : PubMed/NCBI
27	Huang HL, Hsu HP, Shieh SC, Chang YS, Chen WC, Cho CY, Teng CF, Su IJ, Hung WC and Lai MD: Attenuation of argininosuccinate lyase inhibits cancer growth via cyclin A2 and nitric oxide. Mol Cancer Ther. 12:2505–2516. 2013. View Article : Google Scholar : PubMed/NCBI
28	Cunard R and Sharma K: The endoplasmic reticulum stress response and diabetic kidney disease. Am J Physiol Renal Physiol. 300:F1054–F1061. 2011. View Article : Google Scholar : PubMed/NCBI
29	Lee AH, Scapa EF, Cohen DE and Glimcher LH: Regulation of hepatic lipogenesis by the transcription factor XBP1. Science. 320:1492–1496. 2008. View Article : Google Scholar : PubMed/NCBI
30	Wang X, Eno CO, Altman BJ, Zhu Y, Zhao G, Olberding KE, Rathmell JC and Li C: ER stress modulates cellular metabolism. Biochem J. 435:285–296. 2011. View Article : Google Scholar : PubMed/NCBI
31	Clarke HJ, Chambers JE, Liniker E and Marciniak SJ: Endoplasmic reticulum stress in malignancy. Cancer Cell. 25:563–573. 2014. View Article : Google Scholar : PubMed/NCBI
32	Wang G, Yang ZQ and Zhang K: Endoplasmic reticulum stress response in cancer: Molecular mechanism and therapeutic potential. Am J Transl Res. 2:65–74. 2010.PubMed/NCBI
33	Malhi H and Kaufman RJ: Endoplasmic reticulum stress in liver disease. J Hepatol. 54:795–809. 2011. View Article : Google Scholar
34	Ozcan U, Cao Q, Yilmaz E, Lee AH, Iwakoshi NN, Ozdelen E, Tuncman G, Görgün C, Glimcher LH and Hotamisligil GS: Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes. Science. 306:457–461. 2004. View Article : Google Scholar : PubMed/NCBI
35	Barbosa-Tessmann IP, Chen C, Zhong C, Schuster SM, Nick HS and Kilberg MS: Activation of the unfolded protein response pathway induces human asparagine synthetase gene expression. J Biol Chem. 274:31139–31144. 1999. View Article : Google Scholar : PubMed/NCBI
36	Okada T, Yoshida H, Akazawa R, Negishi M and Mori K: Distinct roles of activating transcription factor 6 (ATF6) and double-stranded RNA-activated protein kinase-like endoplasmic reticulum kinase (PERK) in transcription during the mammalian unfolded protein response. Biochem J. 366:585–594. 2002. View Article : Google Scholar : PubMed/NCBI
37	Liang XH, Jackson S, Seaman M, Brown K, Kempkes B, Hibshoosh H and Levine B: Induction of autophagy and inhibition of tumorigenesis by beclin 1. Nature. 402:672–676. 1999. View Article : Google Scholar : PubMed/NCBI
38	Oyadomari S, Gotoh T, Aoyagi K, Araki E, Shichiri M and Mori M: Coinduction of endothelial nitric oxide synthase and arginine recycling enzymes in aorta of diabetic rats. Nitric Oxide. 5:252–260. 2001. View Article : Google Scholar : PubMed/NCBI
39	Korde Choudhari S, Sridharan G, Gadbail A and Poornima V: Nitric oxide and oral cancer: A review. Oral Oncol. 48:475–483. 2012. View Article : Google Scholar : PubMed/NCBI
40	Lechner M, Lirk P and Rieder J: Inducible nitric oxide synthase (iNOS) in tumor biology: The two sides of the same coin. Semin Cancer Biol. 15:277–289. 2005. View Article : Google Scholar : PubMed/NCBI
41	Curtis C, Shah SP, Chin SF, Turashvili G, Rueda OM, Dunning MJ, Speed D, Lynch AG, Samarajiwa S, Yuan Y, et al: The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature. 486:346–352. 2012.PubMed/NCBI